Journals / Göztepe Tıp Dergisi / 2011 / Cilt: 26 - Sayı: 2

Effetcts of anti TNF therapy on bone mineral dansity in rheumatoid arthritis:a retrospective study

Romatoid artritli hastalarda TNF alfa blokörleri tedavisinin kemik mineral yoğunluğu üzerine etkisinin retrospektif değerlendirilmesi

Pages
58–62
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Statistically meaningful correlation between BMD and anti TNF a therapy was not established (p>0,05).Conclusion: Statistically meaningful correlation between BMD and anti TNF a therapy was not established.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Aim of this study is to evaluate the bone mineral density of rheumatoid artritis patients (RA) on anti TNF a therapy and without anti TNF a therapy.Materials and Methods: 32 patient (30 female, 2 male), who were attended to pysical medicine and rehabilitation outpatient clinic and rheumatology outpatient clinic in Göztepe Education and Research Hospital and diagnosed as RA according to ACR criteria, were included in the research.
📊
Key Findings & Data:Patients were evaluated according to demographic data, received therapy, duration of RA, menopause status, disease activity score-DAS 28, lumbar AP and femur neck DXA measurements. "iResults: Mean age of patients was 53.31 ±8.2 years.
💡
Conclusion & Impact:Statistically meaningful correlation between BMD and anti TNF a therapy was not established (p>0,05).Conclusion: Statistically meaningful correlation between BMD and anti TNF a therapy was not established.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Aim of this study is to evaluate the bone mineral density of rheumatoid artritis patients (RA) on anti TNF a therapy and without anti TNF a therapy.Materials and Methods: 32 patient (30 female, 2 male), who were attended to pysical medicine and rehabilitation outpatient clinic and rheumatology outpatient clinic in Göztepe Education and Research Hospital and diagnosed as RA according to ACR criteria, were included in the research. Study was designed as a retrospective research. Patients were evaluated according to demographic data, received therapy, duration of RA, menopause status, disease activity score-DAS 28, lumbar AP and femur neck DXA measurements. "iResults: Mean age of patients was 53.31 ±8.2 years. Mean VK1 of patients was 29.72+5.17 (kg!m2), RA duration was 12.7±8.7 years. A total of 12 (37.5 %) patients used anti TNF a therapy. Statistically meaningful correlation between BMD and anti TNF a therapy was not established (p>0,05).Conclusion: Statistically meaningful correlation between BMD and anti TNF a therapy was not established.

Özet

Amaç: Bu çalışmanın amacı, anti TNF alfa tedavisi alan ve almayan Romatoid Artrit(RA) hastalarını kemik mineral yoğunlukları yönünden karşılaştırmaktır.Gereç ve Yöntem: Çalışmaya Sağlık Bakanlığı İstanbul Göztepe Eğitim ve Araştırma Hastanesi Romatoloji ve Fizik Tedavi ve Rehabilitasyon polikliniklerine başvuran, ACR kriterlerine göre RA tartısı almış olan 32 (30 kadın, 2 erkek) hasta alındı. Hastalar retrospektif olarak değerlendirildi. Metotreksat (MTX) ve/veya düşük doz kortikosteroid (KS) (5-10 mgr/giin) tedavisi alan hastalar (Grup 1, n-20) ile MTX ve/veya düşük doz KS (5-10 mgr/giin) tedavisiyle birlikte anti-TNF alfa tedavisi (adalimumab, inflitıksimab, etanercept) alan (Grup 2, n:12) hastalar karşılaştırıldı. Hastalar, demografik özellikleri, aldıkları tedaviler, hastalık süreleri, menopoz durumları, hastalık aktiviteleri (disease activity score-D AS 28) ve lonıber AP ve femur boynu DXA ölçümleri yönünden incelendi.Bulgular: Çalışmaya alınan hastaların yaş ortalaması 53.31 ±8.2 (yıl), VKİ ortalamaları 29.72+5.17 (kg/m2), hastalık süresi ortalamaları 12.7±8.7 (yıl) idi. Hastaların 12'si (% 37,5) anti-TNF alfa tedavisi almaktaydı. Anti-TNF alfa kullanımıyla DEXA ölçüm sonuçları arasında istatistiksel olarak anlamlı ilişki tespit edilmedi (p>0,05).Sonuç: Bu çalışmada anti-TNF alfa kullanımıyla DXA ölçümleri arasında istatistiksel anlamlı ilişki bulunmadı. RA'da anti TNF alfa tedavisinin kemik mineral yoğunluğu üzerine etkisinin değerlendirilmesi için prospektif, iyi dizayn edilmiş, hasta sayısının fazla olduğu kontrollü çalışmalara ihtiyaç vardır.

🔖

Cite This Article

YUMUŞAKHUYLU, Y., İÇAĞASIOĞLU, A., OĞUZ, M. F., SELİMOĞLU, E., TURGUT, T. S., ATLIĞ, R. Ş. (2022). Effetcts of anti TNF therapy on bone mineral dansity in rheumatoid arthritis:a retrospective study. Göztepe Tıp Dergisi, Cilt: 26 - Sayı: 2, 58–62. https://ajindex.com/articles/526145

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Gümüşdiş G, Doğanavşargil E. Klinik Romatoloji, Deniz Matbası, İstanbul, 269-278, 1999
  2. Haugeberg G, Orstavik RE, Uhlig T, et al. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. Arthritis Rheum 2002;(46): 1720-1728.
  3. Laan RF, Riel PL, Putte L. Bone mass in patients with rheumatoid arthritis.Ann Rheum Dis 1992;51(6):826-832. http://dx.d0i.0rg/l 0.1136/ard.51.6.826 PMid: 1616375 PMCid: 1004760 4. Güler M, Bijsterbosch J, Goekoop-Ruiterman Y, et al. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis 2007;(66): 1508-1512. PMid: 17456523 PMCid:2111640 5. Araşıl T, Atalay F, Biberoğlu S. Osteoporoz. 2. baskı, Güneş Kitabevi, Ankara, 82-83, 2005
  4. Ammann P, Rizzoli R, Bonjour JP, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss cause-d by estrogen deficiency. J Clin Invest 1997;(99): 1699-1703. http://dx.doi.org/10.1172/JCI119333 PMid:9120014 PMCid:507990 7. Roggia C, Gao Y, Cenci S, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001;(98): 13960-13965. http://dx.doi.org/10.1073/pnas.251534698 PMid: 11717453 PMCid:61149 8. Mark S. McMahon, MD, and Yasuyoshi U, et al. Does Anti-TNF-Alpha Have a Role in the Treatment of Osteoporosis. Bulletin of the NYU Hospital for Joint Diseases 2008;66(4): 280-281. PMid: 19093904 9. Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;(94):646-650. PMid: 8506892 10. Verhoeven AC, Boers M, Koppele JM, et al. Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-doseprednisolone. Rheumatology 2001;(40): 1231 -1237. http://dx.doi.org/10.1093/rheumatology/40.11.1231 PMid: 11709606 11. Shimizu S, Shiozawa S, Shiozawa K, et al. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 1985;28(1 ):25-31. http://dx.doi.org/10.1002/art. 1780280105 12. Butler DM, Malfait AM, Mason LJ, et al. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 1997;159(6):2867-2876. PMid:9300710 13. Haugeberg G,